To fund breakthrough ideas, don't seek consensus. Instead, identify proposals that are highly polarizing among experts—where half think it's brilliant and the other half thinks it's terrible. This indicates a departure from the norm and holds the potential for true innovation.

Top-down mandates from authorities have a history of being flawed, from the food pyramid to the FDA's stance on opioids. True progress emerges not from command-and-control edicts but from a decentralized system that allows for thousands of experiments. Protecting the freedom for most to fail is what allows a few breakthrough ideas to succeed and benefit everyone.

The fund backs underfunded, high-risk ideas that others pass on. The goal isn't just to find a unicorn; it's to contribute to science by definitively disproving a hypothesis. A failure is viewed as "crossing out a wrong answer" for the entire field.

Eric Weinstein’s concept of a 'distributed idea suppression complex' argues that heavy government funding, centralized journals, and peer review stifle innovation. Capital flows to politically favored trajectories, not necessarily the most promising ones, disincentivizing challenges to the status quo.

The public and politicians expect scientific funding to yield guaranteed results. This forces a focus on safe, incremental research. To achieve major breakthroughs for issues like climate change, society must understand that failure is a vital part of the scientific process and be willing to fund high-risk, high-reward 'gamble' projects.

Stelios Papadopoulos argues that major drug breakthroughs are stochastic events driven by individual intuition, luck, and counterintuitive thinking, not predictable R&D systems. He states that if discovery could be systematized by AI or process, no company would have an edge.

Paul Romer argues that the process of scientific discovery often leads to 'herding,' where researchers converge on a narrow set of ideas. To foster breakthroughs, it's crucial to create incentives for expressing a wider range of views, even those far from the norm, to prevent premature consensus.

Large institutions, even those designed to foster innovation, are fundamentally conservative. Their investments in real estate, careers, and the status quo make them inherently resistant to the revolutionary change that defines major breakthroughs.

True scientific advancement happens when researchers refuse to accept 'no' as an answer. When immunotherapy was dismissed for lung cancer, pioneers investigated why it worked in melanoma but not other cancers. This mindset—questioning failures and studying successes—is key to turning scientific impossibilities into standard treatments.